Cytomegalovirus (CMV): Transmission, Risks, and Prevention

What Is CMV?

Human herpesvirus 5 (HHV-5). Ubiquitous: 50–80% of adults infected by age 40. Once infected, virus remains latent for life; can reactivate if immunity wanes.

Transmission

  • Direct contact with infectious body fluids: saliva, urine, blood, semen, cervical secretions, breast milk, tears.
  • Common routes: kissing, sexual contact, sharing utensils/cups, diaper changing, transfusion, transplant.
  • Vertical: mother → fetus (congenital CMV) – primary infection in pregnancy = 30–40% transmission; reactivation = 1–2%.

Clinical Manifestations

PopulationPresentation
Immunocompetent adult/childUsually asymptomatic; mono-like syndrome (fever, fatigue, lymphadenopathy, hepatitis) – 10%.
Immunocompromised (HIV/AIDS <200 CD4, transplant, chemo)Retinitis (vision loss), colitis, esophagitis, pneumonitis, encephalitis, neuropathy. Sight/life-threatening.
Congenital CMV (1 in 200 births)90% asymptomatic at birth. 10–15% symptomatic: petechiae, hepatosplenomegaly, jaundice, microcephaly, IUGR, SNHL, chorioretinitis, neurodevelopmental delay.
Perinatal (breast milk/birth canal)Usually benign in term infants; can cause pneumonia, hepatitis, sepsis in preterms.

Diagnosis

  • PCR (viral DNA) – blood, urine, saliva, CSF, amniotic fluid.
  • Antigenemia (pp65) – quantitative, rapid.
  • IgG/IgM serology – past vs. recent infection (IgM false + common).
  • Culture – slow, less sensitive.

Treatment

  • Antivirals: Ganciclovir, valganciclovir, foscarnet, cidofovir, maribavir, letermovir.
  • Indications: Sight/life-threatening disease in immunocompromised; congenital CMV with CNS involvement (valganciclovir 6 months improves hearing/developmental outcomes).
  • Prophylaxis/preemptive: Transplant recipients (valganciclovir/letermovir).

Prevention (Especially in Pregnancy)

  • Hand hygiene after diaper changes, wiping noses.
  • Don’t share food, cups, utensils with young children.
  • Condoms during sex if partner status unknown.
  • No licensed vaccine yet (several in trials).

CMV is common and usually harmless, but devastating in vulnerable groups. Awareness and hygiene reduce risk.

Viral Infections - Related Articles